Search results for "DISEASE PROGRESSION"

showing 10 items of 835 documents

Design and Baseline Characteristics of the HELP Study: An Extended and Long-Term Observation of Pathological Myopia in Caucasians.

2017

<b><i>Purpose:</i></b> To assess the natural disease progression of high myopia in Caucasians considered at risk for the development of myopic choroidal neovascularization (mCNV). <b><i>Methods:</i></b> Subjects were recruited in 25 clinical sites between June 2014 and June 2016. Main inclusion criteria included axial length of ≥26 mm, best-corrected visual acuity ≥0.05 decimal equivalent and presence of at least one out of five predefined morphological disease risk criteria. These were (1) subfoveal choroidal thinning < 50 µm, (2) enhanced choroidal curvature length > 6,300 µm, (3) lacquer cracks, (4) patchy atrophy &#x3…

AdultMalemedicine.medical_specialtyVisual acuityVisual AcuityDiseaseWhite People03 medical and health sciencesYoung Adult0302 clinical medicineAtrophyMyopic choroidal neovascularizationOphthalmologySurveys and QuestionnairesmedicineHumansProspective StudiesFluorescein AngiographyAgedAged 80 and overbusiness.industryChoroidPathological myopiaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesSensory SystemsChoroidal NeovascularizationClinical trialNatural historyOphthalmologyAxial Length EyeResearch DesignBaseline characteristicsMyopia Degenerative030221 ophthalmology & optometryDisease ProgressionFemalesense organsmedicine.symptomAtrophybusiness030217 neurology & neurosurgeryTomography Optical CoherenceFollow-Up StudiesOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
researchProduct

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

2011

SUMMARYOptimal antiretroviral strategies for HIV-infected patients still need to be established. To this end a decision tree including different antiretroviral strategies that could be adopted for HIV-infected patients was built. A 10-year follow-up was simulated by using transitional probabilities estimated from a large cohort using a time-homogeneous Markov model. The desired outcome was for patients to maintain a CD4 cell count of >500 cells/mm3without experiencing AIDS or death. For patients with a baseline HIV viral load ⩾5 log10copies/ml, boosted protease inhibitor-based immediate highly active antiretroviral therapy (HAART) allowed them to spend 12% more time with CD4 ⩾500/mm3than…

AdultMalemedicine.medical_specialty[ INFO ] Computer Science [cs]EpidemiologyAnti-HIV AgentsDecision treeHIV InfectionsDrug Administration ScheduleCohort Studies03 medical and health sciences0302 clinical medicineLife ExpectancyAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActiveHiv infected patientsMedicineHumansProtease inhibitor (pharmacology)In patient[INFO]Computer Science [cs]Computer Simulation030212 general & internal medicineCd4 cell countComputingMilieux_MISCELLANEOUS0303 health sciences030306 microbiologybusiness.industryDecision TreesMiddle AgedViral Loadmedicine.diseaseAntiretroviral therapyMarkov Chains3. Good healthCD4 Lymphocyte CountInfectious DiseasesTreatment OutcomeImmunologyDisease ProgressionFemalebusinessViral loadFollow-Up StudiesEpidemiology and infection
researchProduct

Progression of Coronary Artery Calcification in Predialysis Patients

2006

<i>Background:</i> In patients on dialysis coronary artery calcification (CAC) rapidly proceeds due to impaired mineral metabolism and/or exogenous calcium load. Progression has not been assessed in patients with chronic kidney disease not yet requiring dialysis (CKD patients). In this study, rate and determinants of CAC progression have been evaluated in CKD patients who are exposed to minor derangement of mineral metabolism and calcium load. <i>Methods:</i> Consecutive patients were enrolled. Exclusion criteria were: symptomatic coronary disease, arrhythmia, myocardial infarction, and diabetes. Serum calcium, phosphorus, parathyroid hormone, homocysteine, C-reactiv…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentchemistry.chemical_elementCoronary Artery DiseaseCalciumCoronary artery diseaseRenal DialysisCoronary artery calcification Predialysis patients Phosphorus Progression of calcificationCalcinosisInternal medicinemedicineHumansMineral metabolismIn patientDialysisbusiness.industryDisease progressionCalcinosisnutritional and metabolic diseasesMiddle Agedmedicine.diseaseRadiographychemistryNephrologyCoronary artery calcificationChronic DiseaseDisease ProgressionCardiologyFemaleKidney DiseasesbusinessAmerican Journal of Nephrology
researchProduct

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020

Abstract An ever-expanding number of disease-modifying drugs for multiple sclerosis have become available in recent years, after demonstrating efficacy in clinical trials. In the real-world setting, however, disease-modifying drugs are prescribed in patient populations that differ from those included in pivotal studies, where extreme age patients are usually excluded or under-represented. In this multicentre, observational, retrospective Italian cohort study, we evaluated treatment exposure in three cohorts of patients with relapsing-remitting multiple sclerosis defined by age at onset: paediatric-onset (≤18 years), adult-onset (18–49 years) and late-onset multiple sclerosis (≥50 years). We…

AdultMalemedicine.medical_specialtyneuroinflammationCohort Studies03 medical and health sciences0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansDisabled Persons030212 general & internal medicineProspective StudiesRisk factorclinical trials; clinically isolated syndrome; demyelination; multiple sclerosis epidemiology; neuroinflammationRetrospective Studiesclinical trialsClinically isolated syndromeExpanded Disability Status ScaleProportional hazards modelbusiness.industryHazard ratioMiddle AgedItalyAntirheumatic Agentsclinically isolated syndromeCohortDisease Progressionmultiple sclerosis epidemiologySettore MED/26 - NeurologiaFemaleNeurology (clinical)demyelinationAge of onsetbusiness030217 neurology & neurosurgeryCohort studyFollow-Up Studies
researchProduct

Trajectories of Blood Pressure Elevation Preceding Hypertension Onset: An Analysis of the Framingham Heart Study Original Cohort

2018

Importance Given that hypertension remains a leading risk factor for chronic disease globally, there are substantial ongoing efforts to define the optimal range of blood pressure (BP). Objective To identify a common threshold level above which BP rise tends to accelerate in progression toward hypertension. Design, Setting, and Participants This longitudinal, community-based epidemiological cohort study of adults enrolled in Framingham, Massachusetts, included 1252 participants (mean [SD] age, 35.3 [2.7] years) from the Framingham Original Cohort, of whom 790 (63.1%) were women. Each participant contributed up to 28 serial examinations of standardized resting BP measurements between 1948 and…

AdultMalemedicine.medical_specialtysystolic blood pressuresegmented mixed modelHemodynamicsBlood Pressurethreshold value030204 cardiovascular system & hematology03 medical and health sciencesSex Factors0302 clinical medicineFramingham Heart StudyInternal medicineHumansMedicineLongitudinal Studies030212 general & internal medicineAge of OnsetRisk factorAgedAged 80 and overFramingham Risk Scorebusiness.industryBrief ReportAge FactorsMiddle Agedta3121Blood pressureMassachusettsHypertensionCohortDisease ProgressionCardiologyFemaleAge of onsetCardiology and Cardiovascular MedicinebusinessCohort study
researchProduct

Wheat consumption leads to immune activation and symptom worsening in patients with familial mediterranean fever : a pilot randomized trial

2020

We have identified a clinical association between self-reported non-celiac wheat sensitivity (NCWS) and Familial Mediterranean Fever (FMF). Objectives: A) To determine whether a 2-week double-blind placebo-controlled (DBPC) cross-over wheat vs. rice challenge exacerbates the clinical manifestations of FMF

AdultMalenon-celiac wheat sensitivityCD14 lymphocytesLipopolysaccharide Receptors610 Medizinlcsh:TX341-641Wheat HypersensitivityMonocytesArticleDouble-Blind MethodAIDAI score610 Medical sciencesHumansTriticumCross-Over Studiesinterleukin-1betaTumor Necrosis Factor-alphaCD14 lymphocytefood and beveragesFamilial Mediterranean FeverDisease ProgressionFemaletumor necrosis factor-αlcsh:Nutrition. Foods and food supplyamylase trypsin inhibitor
researchProduct

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct

Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Societe de Pneumo…

2016

Revue des Maladies Respiratoires - In Press.Proof corrected by the author Available online since samedi 16 avril 2016

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescent[SDV]Life Sciences [q-bio]MEDLINEYoung Adult03 medical and health sciences0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesPulmonary medicinePulmonary MedicinemedicineHumansAsthmatic patient030212 general & internal medicineYoung adultChildSocieties MedicalComputingMilieux_MISCELLANEOUSMonitoring PhysiologicAsthmaAsthma therapy[ SDV ] Life Sciences [q-bio]business.industryDisease progressionasthmamedicine.disease3. Good healthasthme[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030228 respiratory systemDisease ProgressionFrancebusiness
researchProduct

15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.

2008

Established histopathological criteria divide invasive breast carcinomas into defined groups. Ductal of no specific type and lobular are the two major subtypes accounting for around 75 and 15% of all cases, respectively. The remaining 10% include rarer types such as tubular, cribriform, mucinous, papillary, medullary, metaplastic, and apocrine breast carcinomas. Molecular profiling technologies, on the other hand, subdivide breast tumors into five subtypes, basal-like, luminal A, luminal B, normal breast tissue-like, and ERBB2-positive, that have different prognostic characteristics. An additional subclass termed "molecular apocrine" has recently been described, but these lesions did not ex…

AdultSilver StainingBreast NeoplasmsBiologyProteomicsBiochemistrySubclassAnalytical ChemistryImmunophenotypingCohort StudiesBreast cancerCoenzyme A LigasesmedicineBiomarkers TumorHumansElectrophoresis Gel Two-DimensionalNeoplasm Invasivenessskin and connective tissue diseasesMolecular BiologyAgedAged 80 and overTissue microarrayParaffin EmbeddingApocrineMiddle Agedmedicine.diseaseImmunohistochemistryApocrine GlandsPhenotypeTissue Array AnalysisImmunologyCancer researchDisease ProgressionHydroxyprostaglandin DehydrogenasesImmunohistochemistryFemaleApocrine CellBreast carcinomaMolecularcellular proteomics : MCP
researchProduct

Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.

2009

Hurler-Scheie syndrome is caused by alpha-l-iduronidase deficiency. Enzyme replacement therapy (ERT) can improve physical capacity and reduces organomegaly. However, the effect on bradytrophic connective tissue is limited. As intravenously administered enzyme cannot cross the blood-brain barrier, the therapy of choice for the more severe Hurler syndrome is haematopoietic stem cell transplantation (HCT). In the more attenuated Scheie syndrome, neurological impairment is less severe; therefore, ERT may be appropriate to treat these patients. Information on long-term outcome in Scheie patients undergoing ERT is scarce. We report a 38-year-old female Scheie patient who has been on ERT for 8 yea…

Adultcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyMucopolysaccharidosis IMyelopathyIduronidaseSpinal cord compressionMucopolysaccharidosis IGeneticsmedicineHumansEnzyme Replacement TherapyHurler syndromeGenetics (clinical)business.industryHematopoietic Stem Cell Transplantationnutritional and metabolic diseasesBrainEnzyme replacement therapymedicine.diseaseSpinal cordSurgeryTransplantationmedicine.anatomical_structureCervical VertebraeDisease ProgressionFemaleScheie syndromebusinessSpinal Cord CompressionJournal of inherited metabolic disease
researchProduct